Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned
Novo Nordisk said its highly anticipated Phase 3 readout showed that CagriSema only managed 22.7% weight loss at 68 weeks, failing to hit the 25 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
